Patients initially randomized to adalimumab + MTX displayed better outcomes , particularly in prevention of radiographic progression ( modified total Sharp score change = 4.0 , 8.8 , 11.0 at Year 10 for the initial adalimumab + MTX , adalimumab , and MTX arms , respectively ) .